산화물 첨가에 의한 알루미나의 물성변화 및 알카리 용액에서의 부식성 연구

송완,김기주 ( W . Song,K . J . Kim ) 한국부식방식학회 1996 Corrosion Science and Technology Vol.25 No.1

High-Intensity Focused Ultrasound as Salvage Therapy for Patients With Recurrent Prostate Cancer After Radiotherapy

송완,정우석,서윤석,장현준,성현환,전황균,정병창,서성일,전성수,최한용,이현무 대한비뇨의학회 2014 Investigative and Clinical Urology Vol.55 No.2

Purpose: To evaluate the oncologic outcomes and postoperative complications ofhigh-intensity focused ultrasound (HIFU) as a salvage therapy after external-beam radiotherapy(EBRT) failure in patients with prostate cancer. Materials and Methods: Between February 2002 and August 2010, we retrospectivelyreviewed the medical records of all patients who underwent salvage HIFU for transrectalultrasound-guided, biopsy-proven locally recurred prostate cancer after EBRTfailure (by ASTRO definition: prostate-specific antigen [PSA] failure after three consecutivePSA increases after a nadir, with the date of failure as the point halfway betweenthe nadir date and the first increase or any increase great enough to provoke initiationof therapy). All patients underwent prostate magnetic resonance imaging and bonescintigraphy and had no evidence of distant metastasis. Biochemical recurrence (BCR)was defined according to the Stuttgart definition (PSA nadir plus 1.2 ng/mL). Results: A total of 13 patients with a median age of 68 years (range, 60–76 years) wereincluded. The median pre-EBRT PSA was 21.12 ng/mL, the pre-HIFU PSA was 4.63ng/mL, and the period of salvage HIFU after EBRT was 32.7 months. The median follow-up after salvage HIFU was 44.5 months. The overall BCR-free rate was 53.8%. Inthe univariate analysis, predictive factors for BCR after salvage HIFU were higherpre-EBRT PSA (p=0.037), pre-HIFU PSA (p=0.015), and short time to nadir (p=0.036). In the multivariate analysis, there were no significant predictive factors for BCR. Thecomplication rate requiring intervention was 38.5%. Conclusions: Salvage HIFU for prostate cancer provides effective oncologic outcomesfor local recurrence after EBRT failure. However, salvage HIFU had a relatively highrate of complications.

Incidence of kidney, bladder, and prostate cancers in Korea: An update

송완,전황균 대한비뇨의학회 2015 Investigative and Clinical Urology Vol.56 No.6

The incidence of cancer is sharply increasing. Cancer is a leading cause of death as well as a significant burden on society. The incidence of urological cancer has shown a higher than average increase and will become an important concern in the future. Therefore, an overall and accurate understanding of the incidence of urological cancer is essential. In this study, which was based on the Korea National Cancer Incidence Database, annual incident cases, age-standardized incidence rates, annual percentage change (APC), and distribution by age group were examined in kidney, bladder, and prostate cancers, respectively. From 1999 to 2011, the total number of each type of urological cancer was as follows: kidney cancer (32,600 cases, 25.5%), bladder cancer (37,950 cases, 29.7%), and prostate cancer (57,332 cases, 44.8%). The age-standardized incidence rates of prostate cancer showed a significant increase with an APC of 12.3% in males. Kidney cancer gradually increased with an APC of 6.0% for both sexes and became the second most frequent urological cancer after 2008. Bladder cancer showed no significant change with an APC of -0.2% for both sexes and has decreased slightly since 2007. The distribution of kidney cancer according to age showed two peaks in the 50- to 54-year-old and 65- to 69-year-old age groups. Bladder and prostate cancers occurred mostly in the 70- to 74-year-old age group. The proportions of male to female were 2.5:1 in kidney cancer and 5.6:1 in bladder cancer. We have summarized the incidence trends of kidney, bladder, and prostate cancers and have provided useful information for screening and management of these cancers in the future.

The clinical utility of transperineal template-guided saturation prostate biopsy for risk stratification after transrectal ultrasound-guided biopsy

송완,강민용,정병창,서성일,전성수,이현무,전황균 대한비뇨의학회 2019 Investigative and Clinical Urology Vol.60 No.6

Purpose: To investigate the clinical utility of transperineal template-guided saturation prostate biopsy (TPB) for risk stratification after transrectal ultrasound (TRUS)-guided biopsy. Materials and Methods: We retrospectively reviewed 155 patients who underwent TPB after previously negative results on TRUS-guided biopsy (n=58) or who were candidates for active surveillance (n=97) fulfilling the PRIAS criteria between May 2017 and November 2018. The patients' clinicopathologic data were reviewed, and the detection of clinically significant cancer (CSC) and upgrading of Gleason grade were identified. Results: The patients' median age and pre-TPB prostate-specific antigen (PSA) value were 65.0 years and 5.74 ng/mL, respectively. A median of 36 biopsy cores was obtained in each patient, with a median TPB core density of 0.88 cores/cm3. Of the 58 males with a previous negative result on TRUS-guided biopsy, prostate cancer (PCa) was detected in 17 males (29.3%), including 8 with CSC. Of the 97 patient candidates for active surveillance, upgrading of the Gleason grade was identified in 31 males (32.0%), 20 with a Gleason grade of 7 (3+4), 6 with a Gleason grade of 7 (4+3), and 5 with a Gleason grade of 8 (4+4). The overall complication rate was 14.8% (23/155), and there were no Clavien–Dindo grade 3 to 5 complications. Conclusions: TPB helps to stratify the risk of PCa that was previously missed or underdiagnosed by TRUS-guided biopsy. TPB might be used as a diagnostic tool to determine risk classification and to help counsel patients with regard to treatment decisions.

3차원 애니메이션을 위한 타이밍 시스템 구현

송완서(Wanseo Song),경민호(Min-Ho Kyung),석혜정(Hae Jung Suk) 한국HCI학회 2006 한국HCI학회 학술대회 Vol.2006 No.2

페인트 종류에 따른 폐석분 압출성형 콘크리트 패널의 외부 마감의 실험적 연구

김한봄(Kim, Han-Bom),송완의(Song, Wan-Eui) 대한건축학회 2013 대한건축학회 학술발표대회 논문집 Vol.33 No.1

작은 신장 종양의 국소 치료

송완(Wan Song),전황균(Hwang Gyun Jeon) 대한비뇨기종양학회 2014 대한비뇨기종양학회지 Vol.12 No.3

Image-guided thermal ablation is accepted as one of non-invasive modalities in the treatment of small renal tumor. Current EAU and AUA guidelines suggest cryoablation and radiofrequency ablation in patients with small renal tumor with/without significant comorbidities. Cryoablation and radiofrequency ablation have been most commonly used in the treatment of small renal tumor. A new ablation modality, microwave ablation, has been of increasing interest in the treatment of small renal tumor. Clinical studies show that ablation therapy is an effective treatment with good clinical outcomes and low risk of complications in selected patients over short- and medium-term periods of time. This article reviews the current published clinical long-term results and updates the results in the procedure, such as cryoablation, radiofrequency ablation and microwave ablation.

임상적으로 유의미한 전립선암의 예측 향상을 위한 Prostate Health Index와 PI-RADS Version 2 조합의 유용성

송완(Wan Song),이충언(Chung Un Lee),정재훈(Jae Hoon Chung),강민용(Minyong Kang),성현환(Hyun Hwan Sung),전황균(Hwang Gyun Jeon),정병창(Byong Chang Jeong),서성일(Seong Il Seo),전성수(Seong Soo Jeon),이현무(Hyun Moo Lee) 대한비뇨기종양학회 2022 대한비뇨기종양학회지 Vol.20 No.2

Purpose: To evaluate the performance of combining prostate health index (PHI) and Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) for detection of clinically significant prostate cancer (csPCa). Materials and Methods: We retrospectively reviewed patients who underwent prostate biopsy for elevated prostate-specific antigen (PSA) ≥2.5 ng/mL and/or abnormal digital rectal examination. Serum markers for PSA, free PSA (fPSA), and [-2] proPSA (p2PSA) were measured, and PHI was calculated as ([p2PSA/fPSA]×[PSA]<SUP>1/2</SUP>). Multiparametric magnetic resonance imaging was performed using a 3.0T scanner and scored using PI-RADSv2. csPCa was defined as either grade group (GG) ≥2 disease or GG1 cancer detected in >2 cores or >50% of positive on biopsy. Univariable and multivariable logistic regression modelling, along with receiver-operating characteristic (ROC) curve analysis was used to predict the probability of csPCa. Results: Of the total 358 patients, 159 (44.4%) were diagnosed with csPCa. On univariable analysis, age, PSA density (PSAD), PHI and PI-RADSv2 were associated with csPCa. The area under the ROC curve (AUC) of baseline model incorporating age and PSAD was 0.663. The AUC of combining PHI and PI-RADSv2 to baseline model was higher than that of PHI alone to baseline model (0.884 vs. 0.807, p<0.0001) and PI-RADSv2 alone to baseline model (0.884 vs. 0.846, p=0.0002), respectively. If biopsy was restricted to patients with PI-RADS 5 as well as PI-RADS 3 or 4 and PHI ≥27, 36.0% of unnecessary biopsy could be avoided at the cost of missing 4.7% of csPCa. Conclusions: The combination of PHI and PI-RADSv2 to baseline model incorporating age and PSAD had higher accuracy for detection of csPCa compared with PHI or PI-RADSv2 alone.

Role of Magnetic Resonance Imaging Using Prostate Imaging-Reporting and Data System Version 2 to Predict Clinically Significant Cancer After Radical Prostatectomy in Very Low-Risk or Low-Risk Prostate Cancer

유재호,송완,김태헌,김찬교,박병관,정병창,서성일,전성수,이현무,최한용,전황균 대한비뇨기종양학회 2017 대한비뇨기종양학회지 Vol.15 No.2

Purpose: To determine the negative predictive value (NPV) of multiparametric magnetic resonance imaging (mp-MRI) for clinically significant cancer (CSC) based on the Prostate Imaging-Reporting and Data System (PI-RADS) version 2 in very low-risk or low-risk prostate cancer patients. Materials and Methods: We retrospectively analyzed 380 patients with low risk of prostate cancer who underwent mp-MRI before radical prostatectomy (RP) from 2011 to 2013. Of the 380 patients, 142 patients were in the very low risk group. CSC at RP was defined as follows: any T3–4, G3+4 with tumor volume>15%, G4+3 or higher. In the very low risk and low risk groups, we analyzed the rate of CSC according to PI-RADS score and calculated the NPV of mp-MRI for detection of CSC. Results: In the low risk group, 20.8% (n=79) of patients had PI-RADS version 2 score 1–2 and 17.4% (n=66) of patients had PI-RADS version 2 score 3. In the very low risk group, 26.8% (n=38) of patients had PI-RADS version 2 score 1–2 and 17.6% (n=25) of patients had PI-RADS version 2 score 3 in the very low risk group. Rates of CSC were 33.7% (n=128) and 16.9% (n=24) in the low risk and very low risk groups, respectively. The NPV of MRI was 93.7% in the very low risk group and 78.6% in the low risk group. Conclusions: The NPV of PI-RADS for CSC is high in the very low risk group, but not in the low risk group. Further multicenter studies are needed to investigate the utility of PI-RADS version 2 for NPV.

Comparison of Perioperative Outcomes of Robotic Versus Laparoscopic Partial Nephrectomy for Complex Renal Tumors (RENAL Nephrometry Score of 7 or Higher)

장현준,송완,서윤석,정우석,전황균,정병창,전성수,이현무,최한용,서성일 대한비뇨의학회 2014 Investigative and Clinical Urology Vol.55 No.12

Purpose: To compare the perioperative outcomes of laparoscopic partial nephrectomy(LPN) and robotic partial nephrectomy (RPN) for moderately or highly complex tumors(RENAL nephrometry score≥7). Materials and Methods: A retrospective analysis was performed for 127 consecutivepatients who underwent either LPN (n=38) or RPN (n=89) between 2007 and 2013. Perioperative outcomes were compared. Results: There were no significant differences between the two groups with respect topatient gender, laterality, RENAL nephrometry score, or body mass index. The RPNgroup had a slightly higher RENAL nephrometry score (7.8 vs. 7.5, p=0.061) and largertumor size (3.0 cm vs. 2.5 cm, p=0.044) but had a lower Charlson comorbidity index (3.7vs. 4.4, p=0.017) than did the LPN group. There were no significant differences withrespect to warm ischemia time, estimated blood loss, intraoperative complications, oroperative time. Only one patient who underwent LPN had a positive surgical margin. There were statistically significant differences in surgical marginal width between theLPN and RPN groups (0.6 cm vs. 0.4 cm, p=0.001). No significant differences in postoperativecomplications were found between the two groups. Owing to potential baselinedifferences between the two groups, we performed a propensity-based matchinganalysis, in which differences in surgical margin width between the LPN and RPNgroups remained statistically significant (0.6 cm vs. 0.4 cm, p=0.029). Conclusions: RPN provides perioperative outcomes comparable to those of LPN andhas the advantage of healthy parenchymal preservation for complex renal tumors(RENAL score≥7).